Objective cerebrospinal fluid response to intraventricular rituximab in indolent CNS lymphoma

Roy E Strowd1, Inas A Abuali, Stuart A Grossman

  • 1Department of Neurology, Johns Hopkins Hospital, David H. Koch Cancer Research Bldg II, 1550 Orleans Street, Room 1M16, Baltimore, MD 21287, USA.

CNS Oncology
|April 24, 2015
PubMed

Indolent CNS lymphomas (CNSLs) are rare and no guidelines exist for management. Recent literature highlights the potential for safe and tolerable intrathecal (IT) delivery of rituximab, a large anti-CD20 monoclonal antibody, for aggressive CNSL. We report a patient with relapsed indolent CNSL who failed systemic rituximab and could not tolerate IT chemotherapies, but had an objective response of 6 months duration to IT rituximab.